Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study: GI Signals

IBD retrospective · n=183 · Aug 12, 2026 · Aliment Pharm Ther · IF 6.7

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

New evidenceCrohn's diseaseulcerative colitisbiologicsanti-TNF

Clinical takeawayIn UC patients with active luminal disease requiring biologic escalation, anti-TNF therapy after vedolizumab shows lower remission rates and durability than anti-TNF as first-line or anti-TNF-to-anti-TNF switching. Consider moving anti-TNF earlier in the biologic sequence for UC, or anti-TNF-to-anti-TNF sequencing rather than vedolizumab-then-anti-TNF. In CD patients with active luminal disease, clinical effectiveness remains similar despite higher discontinuation rates, making the sequencing implications less clear.

What it foundIn UC, anti-TNF therapy after vedolizumab (90% of cases) had significantly lower remission rates at short- and long-term follow-up (p < 0.001) and higher treatment discontinuation (HR 1.69 vs first-line, HR 1.91 vs anti-TNF-to-anti-TNF); in CD, anti-TNF after ustekinumab (62% of cases) showed higher discontinuation (HR 1.55 vs first-line) without significant differences in clinical effectiveness.

ContextCurrent IBD guidelines recommend individualizing biologic sequencing based on prior response, but evidence comparing efficacy after different prior mechanisms of action is limited. This registry study provides observational evidence that in UC, the prior biologic choice affects subsequent anti-TNF effectiveness, with vedolizumab being particularly associated with reduced anti-TNF durability and remission. The CD findings are less decisive.

Refinessuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Crohn’s Disease in Adults' (Lichtenstein GR, Loftus EV, Afzali A, et al., Am J Gastroenterol 2025;120(6):1225-1264). DOI 10.14309/ajg.0000000000003465, PMID 40701562.

Decision at stakewhether to use anti-TNF therapy after prior failure of a non-anti-TNF biologic (vedolizumab, ustekinumab, etc.)

… Ustekinumab (strong, moderate); risankizumab (strong, moderate), and risankizumab over ustekinumab in prior anti-TNF exposure (conditional, low); mirikizumab (strong, moderate); guselkumab IV-then-SC or all-SC (strong, moderate). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS, PERIANAL FISTULIZING, POST-OPERATIVE and 3 more.

Our full summary of this standard

DIAGNOSIS: Use fecal calprotectin (cutoff >50-100 μg/g) to differentiate inflammatory from noninflammatory disease OF THE COLON (strong, moderate). Ileocolonoscopy with biopsies for suspected CD; biopsy uninvolved mucosa to define histologic extent; small bowel imaging is part of the initial workup (key concepts, ungraded). CT enterography is comparable to MR enterography for small bowel detection; MRE should be used PREFERENTIALLY in patients younger than 35 years and where serial examinations are likely, because of radiation avoidance, MRE is not a blanket first choice. Intestinal ultrasound is a radiation-free ADJUNCT to diagnosis and to monitoring treatment response (key concept, ungraded, not a graded recommendation). Perform routine endoscopic CRC surveillance in Crohn's colitis (strong, moderate). MILD-TO-MODERATE / LOWER PROGRESSION RISK: Recommend AGAINST oral mesalamine for induction or maintenance (strong, moderate); sulfasalazine should be considered ONLY for symptomatic mild COLONIC CD (key concept). Controlled ileal-release budesonide 9 mg daily for induction of symptomatic remission in mildly-to-moderately active ileocecal CD (strong, moderate), but recommend AGAINST ileal-release budesonide for MAINTENANCE (strong, low). MODERATE-TO-SEVERE / HIGHER RISK: SUGGEST AGAINST requiring failure of conventional therapy before initiating advanced therapy (conditional, LOW, a permission to skip step-up, not a mandate to start advanced therapy upfront). Oral corticosteroids for short-term induction only (strong, low). Recommend AGAINST azathioprine 1.5-2.5 mg/kg/d and 6-mercaptopurine 0.75-1.5 mg/kg/d for INDUCTION (strong, moderate), but SUGGEST the same agents and doses for MAINTENANCE after corticosteroid-induced remission (conditional, low). Check TPMT before starting azathioprine/6-MP (strong, low); measure NUDT15 variants in patients of East Asian ancestry and TPMT variants in all patients prior to thiopurine initiation (strong, moderate). Methotrexate up to 25 mg weekly IM/SC for maintenance after corticosteroid induction (conditional, low). Anti-TNF agents (IV infliximab, SC adalimumab, SC certolizumab pegol) for induction and maintenance (strong, moderate). Recommend COMBINATION IV infliximab + thiopurine over either agent alone in patients naive to both (strong, moderate). Vedolizumab IV for induction and maintenance of symptomatic remission (strong, moderate). Ustekinumab (strong, moderate); risankizumab (strong, moderate), and risankizumab over ustekinumab in prior anti-TNF exposure (conditional, low); mirikizumab (strong, moderate); guselkumab IV-then-SC or all-SC (strong, moderate). Upadacitinib for induction and maintenance in patients PREVIOUSLY EXPOSED TO ANTI-TNF (strong, moderate), the ACG does not endorse it as a first-line biologic-naive option. SC infliximab and SC vedolizumab are maintenance options in responders to IV induction (strong, moderate). PERIANAL FISTULIZING: infliximab for induction (strong, moderate); adalimumab (conditional, low); antibiotics added to infliximab or adalimumab (conditional, very low); vedolizumab, ustekinumab, upadacitinib each (conditional, VERY LOW). Drain perianal abscesses and place setons before escalating advanced therapy (key concept). POST-OPERATIVE: endoscopic assessment at 6-12 months after surgically induced remission over no monitoring (conditional, moderate); in LOW post-op recurrence risk, continued observation rather than immediate medical therapy (conditional, very low); imidazole antibiotics (metronidazole) 1-2 g/d after small intestinal resection (conditional, low); in HIGH-risk CD, anti-TNF to prevent endoscopic recurrence (STRONG, moderate) and vedolizumab (CONDITIONAL, low), these two are not co-equal. SURGERY/ABSCESS: intra-abdominal abscess >2 cm should be treated with antibiotics plus a drainage procedure, and immunosuppression HELD until drainage is achieved (conditional, low). DISEASE MODIFIERS: counsel active smokers to quit; use NSAIDs with caution; assess stress, depression and anxiety as part of comprehensive care (key concepts).

American College of Gastroenterology, 'ACG Clinical Guideline: Management of Crohn’s Disease in Adults' (Lichtenstein GR, Loftus EV, Afzali A, et al., Am J Gastroenterol 2025;120(6):1225-1264). DOI 10.14309/ajg.0000000000003465, PMID 40701562. · reviewed 2026-07-21 ↗

Yagüe Caballero C … Casas Deza D · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink